Chronic spontaneous urticaria: therapeutic mechanism of omalizumab and assessment of its clinical efficacy
10.3760/cma.j.issn.0412-4030.2019.09.014
- VernacularTitle: 慢性自发性荨麻疹：奥马珠单抗治疗作用机制与疗效评估
- Author:
Yudi CHEN
1
;
Peng GENG
;
Jiahui ZHAO
;
Ping TU
;
Zuotao ZHAO
Author Information
1. Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China
- Publication Type:Review
- Keywords:
Urticaria;
Immunoglobulin epsilon-chains;
Immunoglobulin E;
Omalizumab;
Chronic spontaneous urticaria
- From:
Chinese Journal of Dermatology
2019;52(9):652-655
- CountryChina
- Language:Chinese
-
Abstract:
Chronic spontaneous urticaria (CSU) is characterized by recurrent wheals with severe itching, and greatly affects the life quality of patients. The European guideline on chronic urticaria recommends the anti-IgE monoclonal antibody omalizumab as the only third-line therapy for patients with CSU whose condition can not be controlled by high doses of antihistamines. Although a lot of researches have shown that omalizumab is effective and safe for the treatment of CSU, its therapeutic mechanisms have not yet been fully elucidated. This review summarizes therapeutic mechanisms of omalizumab in the treatment of CSU, and indices for predicting and monitoring its clinical efficacy.
